Skip to main content

Advertisement

Table 3 Mean (95% CI) scores and treatment effect (differences between baseline and post-treatment, 3weeks after intervention) *

From: Effects of a one week multidisciplinary inpatient self-management programme for patients with fibromyalgia: a randomised controlled trial

  SMP group Control group Treatment effect (95 CI) P value Effect size§
Primary outcomes:
Psychological distress (GHQ20) (0 - 60, 0 =no distress) 0.552  
Baseline 27.0 (11.0-57.2) 26.4 (10.0-50.2)   
Post-treatment 25.0 ( 6.0-49.1) 24.6 (10.0-57.2) 0.96 (-2.2 to 4.1)   0.10
Effective Musculoskeletal Consumer Scale (EC-17) (0 -100 , 0= never, 100 =always) 0.016  
Baseline 57.5 (22.1-88.2) 54.3 (0.0-86.8)   
Post-treatment 63.0 (36.8-97.1) 56.8 (1.5-100) 4.26 (0.8 to 7.7)   0.24
Secondary outcomes:     
Self-efficacy pain (10 - 100, 100 = high SE) 0.387  
Baseline 50.6 (18.0-82.0) 51.4 (10.0-98.0)   
Post-treatment 54.8 (16.0-94.0) 52.3 (10.0-82.0) -1.83 (-6.0 to 2.3)   0.12
Self-efficacy symptoms (10 - 100, 100 = high SE) 0.189  
Baseline 57.8 (20.0-93.3) 57.7 (11.7-86.7)   
Post-treatment 61.4 (35.0-91.7) 57.9 (23.3-90.0) 2.63 (-1.3 to 6.6)   0.20
Self –efficacy function (10-100, 100 = high SE) 0.556  
Baseline 77.9 (22.2-100.0) 74.7 (18.9-100.0)   
Post-treatment 77.9 (32.2-100.0) 72.8 (16.7-100.0) 1.02 (-2.4 to 4.4)   0.06
Fibromyalgia Impact Questionnaire (0-10, 0 = low impact) 0.265  
Baseline 59.0 (16.1-89.6) 59.7 (23.9-92.5)   
Post-treatment 55.9 (7.0-90.5) 61.0 (23.2-93.2) -2.76 (-7.7 to 2.1)   0.15
  1. *Adjusted for gender, education, marital status and currently employed (Yes/No).
  2. §Effect sizes were calculated between-group difference divided by the pooled SD of the baseline scores.
  3. (<0.2 trivial; 0.2-0.49, small, 0.5-0.79, moderate, ≥80, large).
  4. GHQ20, General Health Questionnaire, SMP, Self-management programme.